‘I don't feel we lost momentum’: Takeda’s oncology execs sharpen focus after restructuring
Takeda’s revamped R&D strategy means the drugmaker’s oncology leaders are prioritizing work in tumors across thoracic, gastrointestinal (GI) and hematology, while pushing the company’s focus on cell therapy to the backburner.
Takeda’s revamped R&D strategy means the drugmaker’s oncology leaders are prioritizing work in tumors across thoracic, gastrointestinal (GI) and hematology, while pushing the company’s focus on cell therapy to the backburner.
